Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,564Revenue (TTM) $M519Net Margin (%)16.6Altman Z-Score4.5
Enterprise Value $M1,472EPS (TTM) $1.8Operating Margin %23.6Piotroski F-Score6
P/E(ttm)21.0Beneish M-Score-1.8Pre-tax Margin (%)22.3Higher ROA y-yY
Price/Book2.410-y EBITDA Growth Rate %8.0Quick Ratio6.5Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %28.1Current Ratio7.4Lower Leverage y-yN
Price/Free Cash Flow35.3y-y EBITDA Growth Rate %-0.6ROA % (ttm)8.9Higher Current Ratio y-yY
Dividend Yield %--PEG0.8ROE % (ttm)14.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M41.4ROIC % (ttm)15.1Gross Margin Increase y-yN

Gurus Latest Trades with EBS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

EBS is held by these investors:



EBS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
El-Hibri FuadChairman, 10% Owner 2017-11-14Sell40,000$40.37-6.44view
El-Hibri FuadChairman, 10% Owner 2017-11-14Sell40,000$40.37-6.44view
Zoon Kathryn CDirector 2017-11-08Sell2,742$39.2-3.65view
JOULWAN GEORGE ADirector 2017-11-07Sell14,251$41.24-8.41view
Abdun-Nabi DanielPresident & CEO 2017-11-03Sell31,508$42.77-11.69view
El-Hibri FuadChairman, 10% Owner 2017-09-29Sell50,000$40-5.58view
Richard RonaldDirector 2017-09-28Sell23,681$40-5.58view
Havey AdamEVP, Business Operations 2017-09-27Sell7,885$39.5-4.38view
Abdun-Nabi DanielPresident & CEO 2017-09-27Sell15,000$39.92-5.39view
El-Hibri FuadChairman, 10% Owner 2017-09-14Sell25,000$38.5-1.9view

Press Releases about EBS :

Quarterly/Annual Reports about EBS:

News about EBS:

Articles On GuruFocus.com
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Sen Nov 14 2017 
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Sen Nov 14 2017 
Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Oct 19 2017 
Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi Oct 06 2017 
Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Suppl Oct 04 2017 
Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antib Oct 03 2017 
Emergent BioSolutions Announces Closing of New $200 Million Senior Secured Credit Facility Oct 02 2017 
Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow- Sep 25 2017 
Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure Sep 18 2017 
Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Departm Jul 31 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK